{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:55:46Z","timestamp":1793858146205,"version":"4.6.1"},"reference-count":39,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,11,12]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and\/or obstetric morbidity and is associated with systemic lupus erythematosus (SLE). IgG antiphosphatidylserine\/prothrombin complex (aPS\/PT), IgM aPS\/PT and IgG anti-beta 2 glycoprotein 1-domain 1 (a\u03b22GP1-D1) are novel aPLs that have been associated with thrombosis; however, conclusive data are still lacking. It remains unclear how best to incorporate non-criteria autoantibodies into clinical decision-making. The aim of this study was to assess whether these novel aPLs were associated with an increased risk of thrombosis in patients with SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated 341 patients enrolled in the SouThern Alberta Registry for Lupus EryThematosus database with SLE by the American College of Rheumatology or Systemic Lupus International Collaborating Clinics classification criteria. Medical records were reviewed between March 2006 and January 2021 for thrombotic events and serology results for lupus anticoagulant, IgG anticardiolipin, IgG anti-beta 2 glycoprotein 1 (a\u03b22GP1), IgG aPS\/PT, IgM aPS\/PT and IgG a\u03b22GP1-D1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 341 patients with SLE, 59 (17%) met the revised Sapporo lab criteria, and of those 29 (49%) had a major thrombotic event (OR 3.5, 95%\u2009CI 1.9 to 6.3). Among 142 patients who had at least one positive non-criteria autoantibody, 45 (32%) had a major thrombotic event (OR 1.6, 95%\u2009CI 0.97 to 2.6). In a univariate analysis, the IgG aPS\/PT and IgG a\u03b22GP1-D1 were associated with major and all thrombotic events. In a multivariate analysis that controlled for age, sex, prednisone use, SLE disease activity (Systemic Lupus Erythematosus Disease Activity Index\u20142K and the revised Sapporo lab criteria, among the non-criteria aPLs, only IgG aPS\/PT was associated with an increased risk of a major thrombosis (OR 2.2, 95%\u2009CI 1.1 to 4.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In our multivariate analysis, IgG aPS\/PT was associated with a modestly increased risk of thrombotic events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001174","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T23:40:22Z","timestamp":1734046822000},"page":"e001174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9228-1793","authenticated-orcid":false,"given":"Alistair","family":"Murray","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Campbell","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Elaine","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R W","family":"Barber","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Pannu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin J","family":"Fritzler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"St. Pierre","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Skeith","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"2025091515151210000_11.2.e001174.1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2014.01.006","article-title":"Diagnosis and classification of the antiphospholipid syndrome","volume":"48\u201349","author":"G\u00f3mez-Puerta","year":"2014","journal-title":"J Autoimmun"},{"key":"2025091515151210000_11.2.e001174.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"2025091515151210000_11.2.e001174.3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel","year":"2017","journal-title":"J Autoimmun"},{"key":"2025091515151210000_11.2.e001174.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232"},{"key":"2025091515151210000_11.2.e001174.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.77"},{"key":"2025091515151210000_11.2.e001174.6","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(92)90021-5"},{"key":"2025091515151210000_11.2.e001174.7","first-page":"1067","article-title":"Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus","volume":"21","author":"Drenkard","year":"1994","journal-title":"J Rheumatol"},{"key":"2025091515151210000_11.2.e001174.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025091515151210000_11.2.e001174.9","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2025091515151210000_11.2.e001174.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2131-4","article-title":"\u201cNon-criteria\u201d antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025091515151210000_11.2.e001174.11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheum"},{"key":"2025091515151210000_11.2.e001174.12","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/acr.24520","article-title":"Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I\/II Report: Generation and Reduction of Candidate Criteria","volume":"73","author":"Barbhaiya","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091515151210000_11.2.e001174.13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2"},{"key":"2025091515151210000_11.2.e001174.14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/art.41472","article-title":"Reality Check on Antiphospholipid Antibodies in COVID\u201019\u2013Associated Coagulopathy","volume":"73","author":"Gkrouzman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025091515151210000_11.2.e001174.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2027508"},{"key":"2025091515151210000_11.2.e001174.16","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0509"},{"key":"2025091515151210000_11.2.e001174.17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"2025091515151210000_11.2.e001174.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.07.006"},{"key":"2025091515151210000_11.2.e001174.19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10238-019-00555-w","article-title":"Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients","volume":"19","author":"Guo","year":"2019","journal-title":"Clin Exp Med"},{"key":"2025091515151210000_11.2.e001174.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.006"},{"key":"2025091515151210000_11.2.e001174.21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.02.019","article-title":"Clinical significance of anti-domain 1 \u03b22-glycoprotein I antibodies in antiphospholipid syndrome","volume":"153","author":"Iwaniec","year":"2017","journal-title":"Thromb Res"},{"key":"2025091515151210000_11.2.e001174.22","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025091515151210000_11.2.e001174.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.007"},{"key":"2025091515151210000_11.2.e001174.24","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2015.0085"},{"key":"2025091515151210000_11.2.e001174.25","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0409"},{"key":"2025091515151210000_11.2.e001174.26","first-page":"787","article-title":"Antiphosphatidylserine\/prothrombin antibodies in primary antiphospholipid syndrome","volume":"21","author":"Hoxha","year":"2012","journal-title":"Lupus (Los Angel)"},{"key":"2025091515151210000_11.2.e001174.27","first-page":"266","article-title":"Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study","volume":"26","author":"Amengual","year":"2017","journal-title":"Lupus (Los Angel)"},{"key":"2025091515151210000_11.2.e001174.28","first-page":"1571","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus (Los Angel)"},{"key":"2025091515151210000_11.2.e001174.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02413","article-title":"PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome","volume":"9","author":"McDonnell","year":"2018","journal-title":"Front Immunol"},{"key":"2025091515151210000_11.2.e001174.30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1134\/S1607672923700278","article-title":"Antibodies to Domain I \u03b22-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus","volume":"511","author":"Reshetnyak","year":"2023","journal-title":"Dokl Biochem Biophys"},{"key":"2025091515151210000_11.2.e001174.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8421-z"},{"key":"2025091515151210000_11.2.e001174.32","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15785"},{"key":"2025091515151210000_11.2.e001174.33","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1055\/s-0041-1736289","article-title":"Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome","volume":"5","author":"Martins","year":"2021","journal-title":"TH Open"},{"key":"2025091515151210000_11.2.e001174.34","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14633"},{"key":"2025091515151210000_11.2.e001174.35","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13379"},{"key":"2025091515151210000_11.2.e001174.36","first-page":"234","article-title":"Immunoglobulin G is the only anti-beta-2-glycoprotein I isotype that associates with unprovoked thrombotic events among hospital patients","volume":"46","author":"Brusch","year":"2014","journal-title":"Pathology (Phila)"},{"key":"2025091515151210000_11.2.e001174.37","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000107","article-title":"Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE","volume":"3","author":"Domingues","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2025091515151210000_11.2.e001174.38","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.jtha.2023.06.020","article-title":"Survey on APS diagnosis and antithrombotic treatment in patients with ischaemic stroke, other brain ischaemic injury or arterial thromboembolism in other sites","volume":"10","author":"Cohen","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2025091515151210000_11.2.e001174.39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/art.42459","article-title":"Fluctuation of Anti\u2013Domain 1 and Anti\u2013 \u03b2 2 \u2010Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies","volume":"75","author":"Chighizola","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:15:22Z","timestamp":1757974522000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,12]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/lupus-2024-001174"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001174","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}